Spectrum Pharmaceuticals announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum's Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role. Most recently, Ms. Brennan served as Chief Financial Officer of Fore Biotherapeutics, a private precision oncology company pioneering the development of cancer therapies driven by functional genomics.

Prior to Fore, she was the Chief Financial Officer of TELA Bio, Inc., where she guided the company through a successful IPO and follow-on financing. Previously, Ms. Brennan spent 11 years as the Senior Vice President of Treasury and Investor Relations at Integra LifeSciences Holdings Corporation, where she served in numerous capacities and led Integra through a myriad of financings. With Ms. Brennan's announcement, Brittany Bradrick, who was recently appointed to the Board, will now assume the role of Chairperson of the Audit Committee.